• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淀粉样寡聚体作为原纤维的途径上的前体或途径外的竞争者。

Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils.

作者信息

Muschol Martin, Hoyer Wolfgang

机构信息

Department of Physics, University of South Florida, Tampa, FL, United States.

Institut für Physikalische Biologie, Heinrich-Heine-Universität, Düsseldorf, Germany.

出版信息

Front Mol Biosci. 2023 Feb 9;10:1120416. doi: 10.3389/fmolb.2023.1120416. eCollection 2023.

DOI:10.3389/fmolb.2023.1120416
PMID:36845541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9947291/
Abstract

Amyloid Diseases involve the growth of disease specific proteins into amyloid fibrils and their deposition in protein plaques. Amyloid fibril formation is typically preceded by oligomeric intermediates. Despite significant efforts, the specific role fibrils or oligomers play in the etiology of any given amyloid disease remains controversial. In neurodegenerative disease, though, amyloid oligomers are widely considered critical contributors to disease symptoms. Aside from oligomers as inevitable on-pathway precursors of fibril formation, there is significant evidence for off-pathway oligomer formation competing with fibril growth. The distinct mechanisms and pathways of oligomer formation directly affect our understanding under which conditions oligomers emerge and whether their formation is directly coupled to, or distinct from, amyloid fibril formation. In this review, we will discuss the basic energy landscapes underlying the formation of on-pathway off-pathway oligomers, their relation to the related amyloid aggregation kinetics, and their resulting implications for disease etiology. We will review evidence on how differences in the local environment of amyloid assembly can dramatically shift the relative preponderance of oligomers fibrils. Finally, we will comment on gaps in our knowledge of oligomer assembly, of their structure, and on how to assess their relevance to disease etiology.

摘要

淀粉样疾病涉及特定疾病蛋白生长为淀粉样纤维并沉积在蛋白斑块中。淀粉样纤维形成之前通常会有寡聚中间体。尽管付出了巨大努力,但纤维或寡聚体在任何特定淀粉样疾病病因中所起的具体作用仍存在争议。不过,在神经退行性疾病中,淀粉样寡聚体被广泛认为是疾病症状的关键促成因素。除了寡聚体作为纤维形成不可避免的途径前体之外,还有大量证据表明存在与纤维生长竞争的非途径寡聚体形成。寡聚体形成的不同机制和途径直接影响我们对寡聚体在何种条件下出现以及它们的形成是直接与淀粉样纤维形成相关联还是与之不同的理解。在这篇综述中,我们将讨论途径上和途径外寡聚体形成所基于的基本能量景观、它们与相关淀粉样聚集动力学的关系以及它们对疾病病因的影响。我们将综述关于淀粉样组装局部环境差异如何能显著改变寡聚体和纤维相对优势的证据。最后,我们将评论我们在寡聚体组装知识、其结构以及如何评估它们与疾病病因相关性方面的空白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e507/9947291/459b7207a38c/fmolb-10-1120416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e507/9947291/5341b6e2ef58/fmolb-10-1120416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e507/9947291/459b7207a38c/fmolb-10-1120416-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e507/9947291/5341b6e2ef58/fmolb-10-1120416-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e507/9947291/459b7207a38c/fmolb-10-1120416-g002.jpg

相似文献

1
Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils.淀粉样寡聚体作为原纤维的途径上的前体或途径外的竞争者。
Front Mol Biosci. 2023 Feb 9;10:1120416. doi: 10.3389/fmolb.2023.1120416. eCollection 2023.
2
Origin, toxicity and characteristics of two amyloid oligomer polymorphs.两种淀粉样寡聚体多晶型物的起源、毒性及特征
RSC Chem Biol. 2021 Aug 25;2(6):1631-1642. doi: 10.1039/d1cb00081k. eCollection 2021 Dec 2.
3
Structural fingerprints and their evolution during oligomeric vs. oligomer-free amyloid fibril growth.寡聚体与无寡聚体淀粉样纤维生长过程中的结构指纹及其演变。
J Chem Phys. 2013 Sep 28;139(12):121901. doi: 10.1063/1.4811343.
4
Origin of metastable oligomers and their effects on amyloid fibril self-assembly.亚稳态寡聚体的起源及其对淀粉样纤维自组装的影响。
Chem Sci. 2018 Jun 13;9(27):5937-5948. doi: 10.1039/c8sc01479e. eCollection 2018 Jul 21.
5
Defining the pathway of worm-like amyloid fibril formation by the mouse prion protein by delineation of the productive and unproductive oligomerization reactions.通过描绘有生产性和无生产性寡聚反应来定义鼠朊蛋白形成类朊病毒纤维的途径。
Biochemistry. 2011 Feb 22;50(7):1153-61. doi: 10.1021/bi101757x. Epub 2011 Jan 26.
6
Identification of on- and off-pathway oligomers in amyloid fibril formation.淀粉样纤维形成过程中“on-pathway”和“off-pathway”寡聚体的鉴定。
Chem Sci. 2020 Jun 8;11(24):6236-6247. doi: 10.1039/c9sc06501f. eCollection 2020 Jun 28.
7
Self-Assembly of Amyloid Fibrils into 3D Gel Clusters versus 2D Sheets.自组装的淀粉样纤维形成 3D 凝胶簇与 2D 片层。
Biomolecules. 2023 Jan 24;13(2):230. doi: 10.3390/biom13020230.
8
The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.稳定的α-突触核蛋白寡聚体在淀粉样形成的分子事件中的作用。
J Am Chem Soc. 2014 Mar 12;136(10):3859-68. doi: 10.1021/ja411577t. Epub 2014 Feb 28.
9
[Anomalous Kinetics of Amyloidogenesis Suggest a Competition between Oligomers and Fibrils].[淀粉样蛋白生成的异常动力学表明寡聚体与原纤维之间存在竞争]
Mol Biol (Mosk). 2018 Jan-Feb;52(1):73-81. doi: 10.7868/S002689841801010X.
10
Toxic species in amyloid disorders: Oligomers or mature fibrils.淀粉样变疾病中的毒性物质:寡聚体还是成熟纤维。
Ann Indian Acad Neurol. 2015 Apr-Jun;18(2):138-45. doi: 10.4103/0972-2327.144284.

引用本文的文献

1
Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy.靶向淀粉样β寡聚体的纳米材料:阿尔茨海默病诊断与治疗的当前进展及未来方向
Beilstein J Nanotechnol. 2025 Apr 22;16:561-580. doi: 10.3762/bjnano.16.44. eCollection 2025.
2
Detection of non-native species formed during fibrillization of the myocilin olfactomedin domain.在肌纤蛋白嗅觉介质结构域纤维化过程中形成的非天然物种的检测。
Protein Sci. 2025 Apr;34(4):e70063. doi: 10.1002/pro.70063.
3
Multimer Detection System: A Universal Assay System for Differentiating Protein Oligomers from Monomers.

本文引用的文献

1
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.仑卡奈单抗、阿杜卡玛单抗和加内替单抗——对不同形式的淀粉样蛋白-β的结合谱可能解释了阿尔茨海默病临床试验中的疗效和副作用。
Neurotherapeutics. 2023 Jan;20(1):195-206. doi: 10.1007/s13311-022-01308-6. Epub 2022 Oct 17.
2
Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease.小的可溶性α-突触核蛋白聚集物是帕金森病中的毒性物质。
Nat Commun. 2022 Sep 20;13(1):5512. doi: 10.1038/s41467-022-33252-6.
3
Origin, toxicity and characteristics of two amyloid oligomer polymorphs.
多聚体检测系统:一种用于区分蛋白质寡聚体和单体的通用检测系统。
Int J Mol Sci. 2025 Jan 30;26(3):1199. doi: 10.3390/ijms26031199.
4
Functional Biomaterials Derived from Protein Liquid-Liquid Phase Separation and Liquid-to-Solid Transition.源自蛋白质液-液相分离和液-固转变的功能性生物材料。
Adv Mater. 2025 Jun;37(22):e2414703. doi: 10.1002/adma.202414703. Epub 2025 Feb 9.
5
ALZ-801 prevents amyloid β-protein assembly and reduces cytotoxicity: A preclinical experimental study.ALZ-801可预防β-淀粉样蛋白组装并降低细胞毒性:一项临床前实验研究。
FASEB J. 2025 Feb 15;39(3):e70382. doi: 10.1096/fj.202402622R.
6
The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.寻找针对特定和混合病理神经退行性疾病的通用治疗方法。
Int J Mol Sci. 2024 Dec 14;25(24):13424. doi: 10.3390/ijms252413424.
7
Structures of Oligomeric States of Tau Protein, Amyloid-β, α-Synuclein and Prion Protein Implicated in Alzheimer's Disease, Parkinson's Disease and Prionopathies.与阿尔茨海默病、帕金森病和朊病毒病相关的tau蛋白、淀粉样β蛋白、α-突触核蛋白和朊病毒蛋白的寡聚体结构
Int J Mol Sci. 2024 Dec 4;25(23):13049. doi: 10.3390/ijms252313049.
8
Preparation and Characterization of Zn(II)-Stabilized Aβ Oligomers.锌(II)稳定的β淀粉样蛋白寡聚体的制备与表征
ACS Chem Neurosci. 2024 Jul 17;15(14):2586-2599. doi: 10.1021/acschemneuro.4c00084. Epub 2024 Jul 9.
9
Crystal Violet Selectively Detects Aβ Oligomers but Not Fibrils In Vitro and in Alzheimer's Disease Brain Tissue.结晶紫在体外和阿尔茨海默病脑组织中选择性检测 Aβ 寡聚体而不是纤维。
Biomolecules. 2024 May 23;14(6):615. doi: 10.3390/biom14060615.
10
Characterizing Prion-Like Protein Aggregation: Emerging Nanopore-Based Approaches.朊病毒样蛋白聚集的表征:新兴的基于纳米孔的方法。
Small Methods. 2024 Dec;8(12):e2400058. doi: 10.1002/smtd.202400058. Epub 2024 Apr 21.
两种淀粉样寡聚体多晶型物的起源、毒性及特征
RSC Chem Biol. 2021 Aug 25;2(6):1631-1642. doi: 10.1039/d1cb00081k. eCollection 2021 Dec 2.
4
Endo-lysosomal Aβ concentration and pH trigger formation of Aβ oligomers that potently induce Tau missorting.内体溶酶体 Aβ 浓度和 pH 值触发 Aβ 寡聚物的形成,Aβ 寡聚物能强烈诱导 Tau 错误分拣。
Nat Commun. 2021 Jul 30;12(1):4634. doi: 10.1038/s41467-021-24900-4.
5
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.一项针对早期阿尔茨海默病的仑卡奈单抗(抗 Aβ 原纤维抗体)的随机、双盲、2b 期概念验证临床试验。
Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
6
Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.固态 MAS NMR 光谱揭示淀粉样β寡聚物与人朊病毒蛋白复合物的结构细节。
J Biol Chem. 2021 Jan-Jun;296:100499. doi: 10.1016/j.jbc.2021.100499. Epub 2021 Mar 3.
7
Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development.无标记振动成像技术对阿尔茨海默病中不同 Aβ 斑块类型的研究揭示了斑块发展过程中的顺序事件。
Acta Neuropathol Commun. 2020 Dec 11;8(1):222. doi: 10.1186/s40478-020-01091-5.
8
Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life.在转基因小鼠中急性靶向淀粉样前体蛋白可减少晚年的阿尔茨海默病样病理。
Nat Neurosci. 2020 Dec;23(12):1580-1588. doi: 10.1038/s41593-020-00737-w. Epub 2020 Nov 16.
9
Protofibril-Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation.原纤维-纤维相互作用通过阻碍二级成核来抑制淀粉样纤维的组装。
Angew Chem Int Ed Engl. 2021 Feb 8;60(6):3016-3021. doi: 10.1002/anie.202010098. Epub 2020 Dec 11.
10
α-Synuclein aggregation nucleates through liquid-liquid phase separation.α-突触核蛋白通过液-液相分离发生聚集。
Nat Chem. 2020 Aug;12(8):705-716. doi: 10.1038/s41557-020-0465-9. Epub 2020 Jun 8.